Neither method is automatically best for every patient
Delivers the same weight-loss power as the popular weekly injection
Since most people who take GLP-1s eat less, this may affect diet quality and potentially lead to nutritional deficiencies
1.3 In vitro Tirzepatides effects In vivo and in vitro preclinical studies have demonstrated that co-administration of GIP and GLP1 promotes insulin sensitivity, leading to better blood glucose level control, more sustained reduction in food intake and consequently better WL compared to the infusion of a single agent (35, 41, 46), also exerts an additive effect on metabolism of cyclic adenosine monophosphate (cAMP), thus increasing its levels and consequently, potentiating insulin secretion glucose-dependent
Semaglutide produces approximately 15% weight loss, tirzepatide achieves around 21%, and Retatrutide delivers over 24% in clinical trials